関節内補充療法の世界市場-2022-2029

市場概要

関節内補充療法の世界市場規模は、2022年に45億3867万米ドル、2029年には80億5834万米ドルに達すると推定され、予測期間（2022～2029年）にCAGR8.96%で成長するとされています。

関節内補充療法は、滑液の粘性特性を補助するゲル状物質を関節に注入する低侵襲手術で、ヒアルロン酸という濃厚な液体を膝関節に注入して関節痛の軽減や変形性関節症の関節機能状態の改善を図るものです。ヒアルロン酸は滑液の潤滑性を高め、変形性膝関節症の痛みを軽減し、運動機能を向上させる効果があります。

市場力学

変形性関節症や関節リウマチの発症率の上昇、研究開発の増加、痛みを和らげるための関節内補充療法に対する需要の高まりが、世界の関節内補充療法市場を牽引する主な要因となっています。

変形性関節症の有病率および発症率の上昇と技術的進歩の増加が、市場の成長を促進すると予想されます。

関節内補充療法市場は、技術的進歩の高まり、研究開発の増加、変形性関節症における関節内補充療法の高い需要によって牽引され、これも関節内補充療法市場を牽引するものと期待されています。また、市場の成長は、ヘルスケアや臨床試験に対する支出の増加にも起因しています。さらに、主要メーカーが技術的に高度な製品を提供していることも、市場の成長に重要な役割を果たすと予想されます。

政府の助成金の増加や変形性関節症の治療に対する意識の高まりは、市場の成長を後押しします。変形性関節症の疼痛管理における関節内補充療法の採用率が高いことも、関節内補充療法市場の促進要因のひとつです。様々な新規製品の発売や調査研究は、市場の成長に寄与しています。

例えば、2021年8月、生化学工業株式会社は、台湾のTCM Biotech International Corporationから変形性膝関節症治療用関節内関節内補充療法単回注射剤「ハイリンク」を発売しました。このハイリンクは、生化学工業の架橋技術による架橋ヒアルロン酸ハイドロゲルを主成分としており、変形性膝関節症の治療に使用されます。粘弾性の高いヒアルロン酸ハイドロゲルが膝の関節腔内に長く留まることで、症状の改善が期待されます。

関節内補充療法に伴う副作用が市場成長の妨げになると予想されます。

しかし、腫れやかゆみ、関節周囲のあざ、注入した膝への液体蓄積といった関節内補充療法使用時の副作用が、世界の関節内補充療法市場成長の足かせとなっています。

COVID-19の影響分析

パンデミックは、世界の財務的な期待、業務、危機対応戦略にマイナスの影響を及ぼしています。COVID-19の発生はヘルスケア産業に深刻な影響を及ぼしています。COVIDの症例が増加したため、様々な研究や臨床試験が延期され、関節内補充療法市場はCOVIDによる莫大な損失を経験しました。様々な取り組み、コラボレーション、合併が世界中で起こっており、市場の成長を後押ししています。例えば、2021年12月、Avanos Medical, Inc.は、変形性膝関節症の痛みに対する関節内補充療法を提供するOrthogenRx Inc.と約1億6,000万米ドルで買収する合意について発表しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 変形性関節症の有病率および発症率の上昇
    • 技術的進歩の増加
  • 抑制要因
    • 関連する副作用
  • 市場機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• プライシング分析
• 規制分析
• 疫学

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、あるいは将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 プロシージャタイプ別

• シングルインジェクション
• 3回注射
• 5本インジェクション

第8章 アプリケーション別

• 変形性膝関節症
• 変形性股関節症
• 変形性肩関節症
• 変形性足関節症

第9章 エンドユーザー別

• 整形外科クリニック
• 病院
• 外来手術センター

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク
• 注目の主要企業リスト

第12章 企業プロファイル

• Anika Therapeutics, Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Seikagaku Corporation
• Bioventus Inc.
• Johnson and Johnson
• Zimmer Biomet
• Sanofi S.A.
• Miravo Healthcare
• Aptissen
• L.G. Chem and Lifesciences Ltd
• F. Hoffmann La Roche

第13章 世界の関節内補充療法市場-DataM

Market Overview

The global viscosupplementation market size was valued at US$ 4,538.67 million in 2022 and is estimated to reach US$ 8,058.34 million by 2029, growing at a CAGR of 8.96% during the forecast period (2022-2029).

Viscosupplementation is a minimally invasive procedure that involves the injection of gel-like substances into a joint to assist the viscous properties of synovial fluid in reducing the joint pain and improves the functional condition of osteoarthritis joints by using a thick fluid called hyaluronate is injected into the knee joint. Hyaluronate helps improve the lubricating properties of the synovial fluid, reduces the pain from osteoarthritis of the knee, and improves mobility.

Market Dynamics

The rising incidence of osteoarthritis and rheumatoid arthritis, increasing research and development, and rising demand for viscosupplementation for relieving pain are the major factors driving the global viscosupplementation market.

The rising prevalence & incidence of osteoarthritis and increasing technological advancements are expected to drive the market's growth.

The viscosupplementation market is driven by rising technological advancements, increasing research & development, and high demand for viscosupplementation in osteoarthritis, which is also expected to drive the viscosupplementation market. The market's growth can also be attributed to the rising expenditure on healthcare and clinical trials. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Rising government funding and increasing awareness of treating osteoarthritis will boost market growth. Another driving factor for the viscosupplementation market is the high adoption rate of viscosupplementation for osteoarthritis pain management. Various novel product launches and research studies contribute to the market's growth.

For instance, in Aug 2021, Seikagaku Corporation launched its Hylink, an intra-articular viscosupplement single injection for knee osteoarthritis treatment in Taiwan, by TCM Biotech International Corporation. This HyLink is used for knee osteoarthritis treatment as its main ingredient, cross-linked hyaluronate hydrogel, is made by crosslinking technology of Seikagaku. It is expected to show improvement in symptoms as highly viscoelastic hyaluronate hydrogel will remain in the joint cavity of the knee for a longer duration.

Side effects associated with viscosupplementation are expected to hamper market growth.

However, the side effects of using viscosupplementation, like swelling, itching, bruising around the joint, and fluid accumulation in the injected knee, hamper the global viscosupplementation market growth.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The Viscosupplementation market has experienced huge losses due to COVID, as various research and clinical trials got postponed due to the increasing cases of COVID. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Dec 2021, Avanos Medical, Inc. announced about its agreement to acquisition with OrthogenRx Inc., a viscosupplementation therapies provider for knee osteoarthritis pain, for around $160 million.

Segment Analysis

The knee osteoarthritis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Knee osteoarthritis is a joint disorder that is slowly progressive that can be characterized by cartilage degeneration, joint pain, and inflammation; that affects around 350 million people globally. Knee osteoarthritis has various treatment options, from conservative management to knee arthroplasty. The most used non-operative therapies are intra-articular therapies like hyaluronic acid and corticosteroids. This intra-articular hyaluronic acid is the widely used therapy for treating knee pain and inflammation in people with knee osteoarthritis.

The knee osteoarthritis segment dominates the market due to rising global incidences of knee osteoarthritis and the increasing geriatric population. The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in Sep 2021, Bioventus Inc., an active healing innovation company, announced that the American Academy of Orthopaedic Surgeons released their updated clinical practice guidelines that show that Bioventus's DUROLANE treatment and all the high molecular weight cross-linked hyaluronic treatments have shown improvement in patients with knee osteoarthritis.

Geographical Analysis

North America holds the largest market share in the global viscosupplementation market.

North America dominates the global viscosupplementation market, primarily attributed to the rising number of people suffering from osteoarthritis. According to the Centre for Disease Control and Prevention, in 2020, over 32.5 million adults were dealing with osteoarthritis in the United States. Around 14 million people are suffering from rheumatoid arthritis globally. Increasing expenditure on healthcare and raising awareness among people are also contributing to the market's growth in this region. Advancement of technology in these viscosupplementations, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the viscosupplementation market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in Jul 2022, Bioventus Inc., an active healing innovative company, announced its completion of the acquisition of CartiHeal. This acquisition adds CartHeal's active healing solutions portfolio to Bioventus.

Competitive Landscape

The viscosupplementation market is moderately competitive with local and global companies' presence. Anika Therapeutics, Inc., Seikagaku Corporation, Bioventus Inc., Johnson and Johnson, Zimmer Biomet, Sanofi S.A., Miravo Healthcare, Aptissen, L.G. Chem and Lifesciences Ltd, F. Hoffmann La Roche and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Oct 2021, Bioventus Inc., an active healing innovator company, announced the completion of the acquisition of Misonix Inc., regenerative medicine and minimally invasive therapeutic ultrasonic technologies provider developed for better clinical outcomes.

Anika Therapeutics Inc.

Overview: Anika Therapeutics is a company of joint preservation that provides a variety of advancements in orthopedic care early intervention. They provide solutions for soft tissue repair, osteoarthritis pain management, bone-preserving joint technologies, and regenerative therapeutics.

Product Portfolio:

Cingal: This is the first combination viscosupplement approved that provides both cross-linked hyaluronic acid as well as fast-acting steroid advantages for the treatment of osteoarthritis-associated symptoms. It combines Anika's Monovisc HA formulation with triamcinolone hexacetonide, an FDA-approved steroid for treating inflammation and relieving pain.

Key Development: In Jan 2020, Anika Therapeutics Inc., an integrated company of regenerative therapies and joint preservation with products supporting its hyaluronic acid technology platform, announced its acquisition agreement with Parcus Medical, a company of sports medicine and Arthrosurface, a solution provider for joint surface and preservation.

The global viscosupplementation market report would provide access to approx. 45+ market data table, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising prevalence & incidence of osteoarthritis
    • 4.1.1.2. Increasing technological advancements
  • 4.1.2. Restraints:
    • 4.1.2.1. Associated Adverse Effects
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1 Porter's Five Forces Analysis
• 5.2 Supply Chain Analysis
• 5.3 Pricing Analysis
• 5.4 Regulatory Analysis
• 5.5 Epidemiology

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Procedure Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
  • 7.1.2. Market Attractiveness Index, By Procedure Type
• 7.2. Single Injection *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Three Injection
• 7.4. Five Injection

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Knee Osteoarthritis *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Hip Osteoarthritis
• 8.4. Shoulder Osteoarthritis
• 8.5. Ankle Osteoarthritis

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Orthopedic Clinics *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Hospitals
• 9.4. Ambulatory Surgical Centres

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Products Benchmarking
• 11.4. List of Key Companies to Watch

12. Company Profiles

• 12.1. Anika Therapeutics, Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Seikagaku Corporation
• 12.3. Bioventus Inc.
• 12.4. Johnson and Johnson
• 12.5. Zimmer Biomet
• 12.6. Sanofi S.A.
• 12.7. Miravo Healthcare
• 12.8. Aptissen
• 12.9. L.G. Chem and Lifesciences Ltd
• 12.10. F. Hoffmann La Roche

LIST NOT EXHAUSTIVE

13. Global Viscosupplementation Market - DataM

• 13.1. Appendix
• 13.2. About Us and Application
• 13.3. Contact Us